Skip links

Allergy & Immunology Center of Excellence

Supporting patients living with rare allergy and immunology conditions

Orsini’s Allergy & Immunology Center of Excellence launched in 2011 with our first supported product for Hereditary Angioedema. Today we support multiple Allergy & Immunology programs across several conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.​

Explore Our Allergy & Immunology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Dedicated Patient Advocate

Navigate complex conditions like Hereditary Angioedema with a dedicated patient advocate. Gain access to additional support and helpful resources for disease management.

Support

Allergy & Immunology Conditions Supported

Explore the rare allergy and immunology conditions Orsini supports below.

About CD55-Deficient Protein-Losing Enteropathy (CHAPLE) Disease

CHAPLE disease (also known as CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein losing enteropathy, or CD55-deficient protein-losing enteropathy) is an ultra-rare hereditary condition characterized by an inability to regulate complement activity because of mutations in the CD55 gene. In most patients, this leads to potentially life-threatening symptoms beginning in infancy, including abdominal pain, bloody diarrhea, vomiting, malnutrition, slow growth, and edema. There are fewer than 100 patients worldwide who are known to have CHAPLE disease.

CHAPLE Disease Therapies Supported

Full Name Veopoz™ (pozelimab-bbfg)
Drug Veopoz
Manufacturer Regeneron Pharmaceuticals
Route of Administration Intravenous
Site of Care Healthcare Facility
Approved Indication The treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
Disease CD55-deficient protein-losing enteropathy (CHAPLE) Disease
Therapeutic Area Allergy & Immunology, Genetics
Enrollment Form Link Veopoz Enrollment Form
Phone Number 800-438-2375
Fax Number 877-440-0891
Product Website veopoz.com

About Hereditary Angioedema (HAE)

Hereditary angioedema is an inherited genetic disorder that can affect the autoimmune system, causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines, and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger. Untreated, attacks can occur much more frequently, with some reported cases of daily incidents. It’s important to note that you can also be diagnosed with HAE without a family history as some diagnosed HAE patients are a result of a mutated gene, which is called De Novo Mutation.

HAE Therapies Supported

Full Name Berinert® [C1 esterase inhibitor (human)]
Drug Berinert
Manufacturer CSL Behring
Route of Administration Intravenous
Site of Care Home
Approved Indication Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website berinert.com/professional

Full Name Cinryze® [C1 esterase inhibitor (human)]
Drug Cinryze
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE)
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website cinryze.com/hcp

Full Name Firazyr® (icatibant)
Drug Firazyr
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website firazyr.com/hcp

Full Name Haegarda® [C1 esterase inhibitor subcutaneous (human)]
Drug Haegarda
Manufacturer CSL Behring
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website haegarda.com/hcp

Full Name Icatibant Acetate
Drug icatibant acetate
Manufacturer Generic
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918

Full Name Kalbitor® (ecallantide)
Drug Kalbitor
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website kalbitor.com/hcp

Full Name Ruconest® [C1 esterase inhibitor (recombinant)]
Drug Ruconest
Manufacturer Pharming Group
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE)
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Ruconest Patient Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website ruconest.com

Full Name Takhzyro® (lanadelumab-flyo)
Drug Takhzyro
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Takhzyro Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website takhzyro.com

About Nasal Polyps

Nasal polyps are benign, painless growths that develop in the lining of the nasal passages or sinuses. These soft, painless swellings result from chronic inflammation, often linked to conditions like allergies, asthma, or chronic sinusitis. Nasal polyps vary in size and may cause symptoms such as nasal congestion, diminished sense of smell, facial pain, or persistent runny nose. While small polyps may be asymptomatic, larger ones can obstruct airflow and contribute to breathing difficulties. Nasal polyps are prevalent across various age groups, with a higher occurrence in young and middle-aged adults.

Nasal Polyps Therapies Supported

Full Name Sinuva® (mometasone furoate)
Drug Sinuva
Manufacturer Intersect ENT
Route of Administration Sinus Implant
Site of Care Healthcare Facility
Approved Indication The treatment of nasal polyps in patients ≥ 18 years of age who have had ethmoid sinus surgery
Disease Nasal Polyps
Therapeutic Area Allergy & Immunology
Enrollment Form Link Sinuva Enrollment Form
Phone Number 800-356-4354
Fax Number 877-574-0550
Product Website sinuva.com

Primary Immune Deficiency Disorders (PIDD)

Primary immunodeficiency disorders (PIDD) are a group of rare, genetic conditions characterized by a malfunctioning or absent immune system. Individuals with PIDD have weakened defense mechanisms, making them more susceptible to infections. This can lead to recurrent, severe, and often unusual infections that may be difficult to treat. PIDD can manifest in various ways, affecting different components of the immune system. Living with PIDD requires a proactive approach to minimize infection risks and promote overall well-being.

PIID Therapies Supported

Full Name intravenous immunoglobulin (IVIG)
Drug IVIG
Manufacturer Generic
Route of Administration Subcutaneous or Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura (ITP), or chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Disease Primary Immune Deficiency
Therapeutic Area Allergy & Immunology
Enrollment Form Link N/A
Phone Number 847-725-8100